Get started
Author

Emily Linda Alouani

Metastatic site and clinical outcome of patients with deficient mismatch repair metastatic colorectal cancer treated with an immune checkpoint inhibitor in the first-line setting
2023 · Bahar Saberzadeh-Ardestani, Jeremy C. Jones, et al. · European Journal of Cancer · 31
Efficacy of immunotherapy in mismatch repair-deficient advanced colorectal cancer in routine clinical practice. An AGEO study
2023 · E. Alouani, M. Mercier, et al. · ESMO Open · 30
PDF
Chemotherapy and Immune Checkpoint Blockade for Gastric and Gastroesophageal Junction Adenocarcinoma
2023 · Gulam A. Manji, Shing Lee, et al. · JAMA Oncology · 25
Immunosuppressant mycophenolate mofetil for patients with steroid-refractory immune-related hepatitis induced by checkpoint inhibitors in oncology
2023 · Emily Alouani, Ariane Laparra, et al. · European Journal of Cancer · 24
Risk of bowel obstruction in patients with colon cancer responding to immunotherapy: an international case series
2024 · J.R. Platt, J. Allotey, et al. · ESMO Open · 22
Treatments after Immune Checkpoint Inhibitors in Patients with dMMR/MSI Metastatic Colorectal Cancer
2022 · Quang Loc Bui, Léo Mas, et al. · Cancers · 21
PDF
BRAF + EGFR +/- MEK inhibitors after immune checkpoint inhibitors in BRAF V600E mutated and deficient mismatch repair or microsatellite instability high metastatic colorectal cancer
2024 · Margherita Ambrosini, David Tougeron, et al. · European Journal of Cancer · 19
Is there a role for locoregional treatment of the primary tumor in de novo metastatic breast cancer in the era of tailored therapies?
2020 · E. Pons-Tostivint, E. Alouani, et al. · Critical Reviews in Oncology/Hematology · 19
PDF
Early treatment discontinuation in patients with deficient mismatch repair or microsatellite instability high metastatic colorectal cancer receiving immune checkpoint inhibitors
2025 · Julien Taieb, Margherita Ambrosini, et al. · Journal for ImmunoTherapy of Cancer · 18
PDF
Primary resistance to immunotherapy in patients with a dMMR/MSI metastatic gastrointestinal cancer: who is at risk? An AGEO real-world study
2023 · Clémence Flecchia, Edouard Auclin, et al. · British Journal of Cancer · 17
PDF
Prognostic impact of the BRAF V600E mutation in patients with MSI-high metastatic colorectal cancer treated with immune checkpoint inhibitors
2025 · Claire Gallois, Margherita Ambrosini, et al. · European Journal of Cancer · 14
A multicenter study evaluating efficacy of immune checkpoint inhibitors in advanced non-colorectal digestive cancers with microsatellite instability
2024 · Mathilde Moreau, Emily Alouani, et al. · European Journal of Cancer · 13
PDF
Profile and outcome of cancer patients enrolled in contemporary phase I trials
2023 · Emily Alouani, Anas Gazzah, et al. · European Journal of Cancer · 13
Abstract CT009: Phase II trial of perioperative pembrolizumab plus capecitabine and oxaliplatin followed by adjuvant pembrolizumab for resectable gastric and gastroesophageal junction (GC/GEJ) adenocarcinoma
2022 · Alexander Grenander Raufi, Shing Lee, et al. · Cancer Research · 13
Complete pathological response after chemotherapy or immune checkpoint inhibitors in deficient MMR metastatic colorectal cancer: Results of a retrospective multicenter study
2023 · Pauline Marolleau, David Tougeron, et al. · International Journal of Cancer · 11
PDF
Future of immunotherapy in pancreas cancer and the trials, tribulations and successes thus far
2021 · Winston Wong, Emily Alouani, et al. · Seminars in Oncology · 10
Immunotherapy advances in cancers with mismatch repair or proofreading deficiencies
2022 · Emily Alouani, Benoit Rousseau, et al. · Nature Cancer · 9
Real-world efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient biliary tract cancer: An AGEO study
2025 · Iona Campo-Le-Brun, Emma Grapinet, et al. · European Journal of Cancer · 7
Cytotoxic chemotherapy potentiates the immune response and efficacy of combination CXCR4/PD-1 inhibition in models of pancreatic ductal adenocarcinoma
2023 · Alexander G. Raufi, Ilenia Pellicciotta, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 5
PDF
Efficacy of immunotherapy in gastrointestinal (GI) tumors with mismatch repair deficient (MMRd) unusual phenotype: an AGEO real-world study
2025 · Emily Alouani, Julien Taieb, et al. · Journal for ImmunoTherapy of Cancer · 4
PDF
A double-edged sword: unusual multiple severe infections with pralsetinib: a case report and literature review
2024 · François Poumeaud, Marion Jaffrelot, et al. · Frontiers in Medicine · 4
Chemo4MetPanc: A phase II study with combination chemotherapy (gemcitabine and nab-paclitaxel), chemokine (C-X-C) motif receptor 4 inhibitor (motixafortide), and immune checkpoint blockade (cemiplimab) in metastatic treatment naïve pancreas adenocarcinoma (PDAC).
2021 · Ilenia Pellicciotta, Emily Linda Alouani, et al. · Journal of Clinical Oncology · 4
111O The mechanism of mismatch repair deficiency (MMRd) informs survival outcomes derived from immune checkpoint blockade (ICB) across MMRd solid tumors
2025 · V. Randrian, K. Sweeney, et al. · Annals of Oncology · 3
Is survival influenced by metastatic site in synchronous metastatic pancreatic adenocarcinoma (PDAC)? A prospective real-world BACAP study
2025 · E. Alouani, C. Canivet, et al. · ESMO Gastrointestinal Oncology · 2
PDF
143P Efficacy of immunotherapy in gastro-intestinal (GI) tumors with mismatch repair deficient (MMRd) unusual phenotype
2024 · E.L. Alouani, G. Roces, et al. · Annals of Oncology · 2
Works count: 46
Citation count: 346
H-index: 13
I10-index: 16
Year
Topic
Type